Inactive Instrument

Neurotrope, Inc.

Equities

NTRP

US64129T2078

Neurotrope Announces Changes to the Board of Directors and Management

August 05, 2016 at 11:00 pm IST

On August 5, 2016, Neurotrope, Inc announced that it has reached a settlement agreement with Iroquois Master Fund Ltd. and certain of its affiliates with regard to a proposed consent solicitation by Iroquois. As part of the settlement, Paul E. Freiman and Jay M. Haft resigned from the Board of Directors of the Company effective immediately. The Board appointed Mr. Joshua Silverman Chairman of the Board and Dr.Kenneth J. Gorelick to the Board effective immediately.

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	02/20/02	CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	01/20/01	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	10/20/10	CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	06/20/06	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	11/20/11	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	13/20/13	CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	10/20/10	CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease	28/20/28	CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction.	18/20/18	CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc.	17/20/17	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	14/20/14	CI
Neurotrope, Inc. Announces Board Resignations	28/20/28	CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial	22/20/22	CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope	22/20/22	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	12/19/12	CI
Neurotrope Reviews Strategic Alternatives to Maximize Shareholder Value	08/19/08	CI
Neurotrope, Inc. Announces Top-Line Results from Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	09/19/09	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	09/19/09	CI
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease	15/19/15	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	10/19/10	CI
Neurotrope, Inc. Appoints Michael Ciraolo as General Counsel and Chief Operating Officer	01/19/01	CI
Neurotrope Inc Comments on Biogen's Discontinued Phase 3 Trial in Alzheimer's Disease	21/19/21	CI
Neurotrope Inc. Completes Enrollment of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	13/19/13	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	09/19/09	CI
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute	04/19/04	CI

Chart Neurotrope, Inc.

Duration

Period

More charts

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Sector

More about the company